UA87822C2 - Производные нафтилена как ингибиторы цитохрома p450 - Google Patents

Производные нафтилена как ингибиторы цитохрома p450

Info

Publication number
UA87822C2
UA87822C2 UAA200601312A UAA200601312A UA87822C2 UA 87822 C2 UA87822 C2 UA 87822C2 UA A200601312 A UAA200601312 A UA A200601312A UA A200601312 A UAA200601312 A UA A200601312A UA 87822 C2 UA87822 C2 UA 87822C2
Authority
UA
Ukraine
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
UAA200601312A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ванесса Смит
Энтони Найгро
Марк Малвихилл
Кара Сесарио
Патришия Энн Бек
Арлиндо Лукас Кастелано
Original Assignee
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оси Фармасьютикалз, Инк. filed Critical Оси Фармасьютикалз, Инк.
Publication of UA87822C2 publication Critical patent/UA87822C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
UAA200601312A 2003-07-10 2004-12-07 Производные нафтилена как ингибиторы цитохрома p450 UA87822C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10

Publications (1)

Publication Number Publication Date
UA87822C2 true UA87822C2 (ru) 2009-08-25

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200601312A UA87822C2 (ru) 2003-07-10 2004-12-07 Производные нафтилена как ингибиторы цитохрома p450

Country Status (15)

Country Link
EP (1) EP1654236A1 (ru)
JP (1) JP4832295B2 (ru)
KR (1) KR20060052799A (ru)
CN (1) CN1819996B (ru)
AU (1) AU2004257257B2 (ru)
BR (1) BRPI0412424A (ru)
CA (1) CA2532078A1 (ru)
IL (1) IL172812A0 (ru)
IS (1) IS8223A (ru)
MX (1) MXPA06000401A (ru)
NO (1) NO20060114L (ru)
RU (1) RU2363696C2 (ru)
SG (1) SG144941A1 (ru)
UA (1) UA87822C2 (ru)
WO (1) WO2005007631A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1696899A1 (en) * 2003-12-17 2006-09-06 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US8513291B2 (en) 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
KR20180039185A (ko) * 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EP2651905B1 (en) * 2010-12-13 2017-07-19 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
AU2015301891B2 (en) 2014-08-11 2019-12-05 Angion Biomedica Corporation Cytochrome P450 inhibitors and uses thereof
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
AU2015374231B2 (en) 2014-12-31 2020-07-23 Angion Biomedica Corp. Methods and agents for treating disease
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
EP3568395A1 (de) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
TW201837036A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（一）

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (ru) * 1960-05-04
NL131915C (ru) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
ATE293102T1 (de) * 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類

Also Published As

Publication number Publication date
CN1819996B (zh) 2010-10-27
RU2363696C2 (ru) 2009-08-10
WO2005007631A1 (en) 2005-01-27
EP1654236A1 (en) 2006-05-10
KR20060052799A (ko) 2006-05-19
JP4832295B2 (ja) 2011-12-07
SG144941A1 (en) 2008-08-28
MXPA06000401A (es) 2006-03-17
AU2004257257B2 (en) 2011-05-12
IL172812A0 (en) 2006-06-11
CA2532078A1 (en) 2005-01-27
CN1819996A (zh) 2006-08-16
BRPI0412424A (pt) 2006-09-05
RU2006103996A (ru) 2006-07-10
NO20060114L (no) 2006-02-09
JP2007523866A (ja) 2007-08-23
AU2004257257A1 (en) 2005-01-27
IS8223A (is) 2006-01-10

Similar Documents

Publication Publication Date Title
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
TW200728307A (en) Novel spirochromanone derivatives
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
NZ598242A (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
MXPA03006248A (es) Derivados de acido fumarico como inhibidores de nf-kappab.
MX2007004699A (es) Derivados de indol y bencimidazol.
BR0316583A (pt) Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
IL179607A0 (en) Indoles useful in the treatment of inflammation
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
WO2007084728A3 (en) 2-imino-benzimidazoles
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
TW200613289A (en) Prodrugs of hiv protease inhibitors
UA97256C2 (ru) Замещенные пиразолы и триазолы как ингибиторы кбв (кинезин-белок веретена)
WO2007017728A3 (en) Novel heterocyclic compounds
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
HK1111168A1 (en) A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 ß,7ß,15 ß,16 ß - BISMETHYLENE-17a-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID Y-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
DE602005011267D1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors